GSK3 Inhibition – Neuroprotection & Alzheimer’s

Understanding GSK3 and Its Role in Brain Health

GSK3 (Glycogen Synthase Kinase 3) is a key enzyme involved in multiple cellular signaling pathways. While it plays important roles in normal cell function, overactivity of GSK3 is strongly linked to harmful processes in the brain, including excessive inflammation, abnormal tau protein phosphorylation, and neuronal damage.
In Alzheimer’s disease, increased GSK3 activity contributes to the formation of neurofibrillary tangles (tau pathology), promotes neuroinflammation, and accelerates neuronal loss. GSK3 overactivation is also associated with other neurodegenerative conditions and general brain aging. Inhibiting GSK3 has shown potential to reduce these damaging effects and support healthier brain function.

The Role of GSK3 Inhibition

Inhibiting GSK3 can provide dual benefits:
+ Decrease neuroinflammation by reducing pro-inflammatory signaling
+ Neuroprotection by lowering tau hyperphosphorylation and protecting neurons from damage
+ Potential to slow progression of Alzheimer’s disease and other neurodegenerative conditions

We believe targeted inhibition of GSK3 is a promising strategy for protecting brain health, reducing inflammation in the central nervous system, and supporting cognitive function during aging.

Our Research Approach

We are focusing on the discovery of novel GSK3 inhibitors using our proprietary platform:

High-Throughput Screening (HTS)

for Small-Molecule Inhibitors

Using our advanced GFP-based promoter-reporter assays in human cell cultures, we screen thousands of natural and synthetic compounds to identify potent and selective inhibitors of GSK3 expression and activity.

This approach allows us to discover new nutraceutical or pharmaceutical candidates that can reduce brain inflammation and provide neuroprotection with improved safety profiles.

Partnership Opportunities

We offer licensing of discovered compounds, custom research, and technology transfer for all three approaches.

HTS Screening Project: Start at $40,000 – $150,000 + 5% royalty

Gene Therapy Development: Custom pricing (typically $1M – $2M) + 5% royalty

Full technology transfer and offshore lab setup available

Head Office

Tampa
Florida, US

Call Now

312-730-2562
786-307-1256

Email Us

dr.nikolic@ufl.edu